

# **Venous Thrombo-Embolism (VTE)**

## **In Cancer Patients**

### **Essay**

*Submitted for Partial Fulfillment of Master Degree  
In General Surgery*

### **By**

**Hisham Abdel-Hakim Mohamed Ahmed Labib**  
*M.B.B.Ch.*  
*Faculty of Medicine- Mansoura University*

### **Under Supervision of**

**Prof. Dr. Mohamed Naguib Hassan**  
*Professor of General Surgery*  
*Faculty of Medicine- Ain Shams University*

### **Prof. Dr. Amr Kamel Elfeky**

*Professor of General Surgery*  
*Faculty of Medicine - Ain-Shams University*

### **Dr. Mohamed Ahmed Aboul Naga**

*Lecturer of General Surgery*  
*Faculty of Medicine - Ain Shams University*

**Faculty of Medicine**  
**Ain Shams University**  
**2015**


## *Acknowledgement*

*First and foremost thanks to **ALLAH** the Most Gracious, the Most Merciful, for helping me to complete this work.*

*It is of great pleasure to express my deep thanks and sincere gratitude to **Prof. Dr. Mohamed Naguib**, Professor of General Surgery, Faculty of Medicine, Ain-Shams University, for precious scientific supervision derived from his wide experience and kind assistance.*

*I feel very much indebted to **Prof. Dr. Amr Kamel Elfeky**, Professor of General Surgery, Faculty of Medicine, Ain-Shams University, who made this research possible throughout his fatherly attitude and very close supervision and great support in this research and general life.*

*Last but not least, my sincere thankfulness and great gratitude to **Dr. Mohamed Ahmed Aboul Naga**, Lecturer of General Surgery, Faculty of Medicine, Ain-Shams University, for his kind supervision, precious ideas, suggestions, fascinating advises and for time, endless effort and guidance; he generously gave me.*



*Hisham Labib*

A decorative border with floral motifs in pink, yellow, and blue, framing the central text area.

# *Dedication*

To my Mother

To my Father

(Allah shall be merciful)

To my Wife

To my Daughter

# Contents

List of Abbreviations .....	I
List of Tables .....	V
List of Figures .....	VII
<b>Introduction</b> .....	<b>1</b>
<b>Aim of the Study</b> .....	<b>4</b>
<b>Review of Literature</b> .....	
- Chapter (1): Magnitude of the Problem .....	<b>5</b>
- Chapter (2): Pathogenesis of Venous Thromboembolism (VTE) in Cancer Patients .....	<b>12</b>
- Chapter (3): Diagnosis of Venous Thromboembolic Disease (VTE) .....	<b>55</b>
- Chapter (4): Prophylaxis and Treatment.....	<b>81</b>
- Chapter (5): Central Venous Catheter .....	<b>119</b>
<b>Summary</b> .....	<b>127</b>
<b>References</b> .....	<b>132</b>
<b>Arabic Summary</b> .....	<b>--</b>

## ***List of Abbreviations***

<b>Abb.</b>	<b>Full Term</b>
<b>3D</b>	three-dimensional
<b>ACCP, AT9</b>	American college of chest physicians antithrombotic guidelines, 9 <sup>th</sup> edition
<b>ADP</b>	Adenosine diphosphate
<b>ALL</b>	Acute lymphoblastic leukemia
<b>APC</b>	Activated protein C
<b>aPTT</b>	Activated partial thromboplastin
<b>ASCO</b>	American society of clinical oncology
<b>bFGF</b>	Basic fibroblast growth factor
<b>BMI</b>	Body mass index
<b>CATS</b>	Vienna cancer and thrombosis study
<b>CBC</b>	Complete blood count
<b>CI</b>	Confidence interval
<b>COX-2</b>	Cyclo-oxygenase 2
<b>CP</b>	Cancer procoagulant
<b>CrCl</b>	Creatinine clearance
<b>CRP</b>	C-reactive protien
<b>CRT</b>	Catheter related thrombosis
<b>CTPA</b>	Computed Tomography Pulmonary angiography
<b>CVC</b>	Central venous catheter

<b>Abb.</b>	<b>Full Term</b>
<b>CYP</b>	cytochrome
<b>DUS</b>	Duplex ultrasound
<b>DVT</b>	Deep vein thrombosis
<b>EC</b>	endothelial cells
<b>ECM</b>	Extracellular matrix
<b>EGFR</b>	Endothelial growth factor receptor
<b>ESAs</b>	Erythropoiesis stimulating agents
<b>ESMO</b>	European society of medical oncology
<b>F1+2</b>	Prothrombin fragment 1+2
<b>FDA</b>	US Food and Drug Administration
<b>GSM</b>	median grayscale measure
<b>HIT</b>	Heparin induced thrombocytopenia
<b>HR</b>	High risk
<b>IL</b>	Interleukin;
<b>IL-1b</b>	Interleukin-1 beta
<b>INR</b>	international normalized ratio
<b>IPC</b>	Intermittent pneumatic compression
<b>IU</b>	international units
<b>IV</b>	intravenous
<b>IVC</b>	Inferior vena cava
<b>LA</b>	lupus anticoagulant
<b>LMWH</b>	Low molecular weight heparin

<b>Abb.</b>	<b>Full Term</b>
<b>MP</b>	Microparticles
<b>NCCN</b>	National comprehensive cancer network
<b>NNT</b>	Number needed to treat
<b>NOA</b>	New oral anticoagulants
<b>NPV</b>	Negative predictive value
<b>PAI</b>	plasminogen activator inhibitor
<b>PAI-1</b>	Plasminogen activator inhibitor-1
<b>PAR</b>	Protease-activated receptors
<b>PDGF</b>	Platelet-derived growth factor
<b>PE</b>	Pulmonary embolism
<b>P-gp</b>	P-glycoprotein.
<b>PICCs</b>	Peripherally inserted central catheters
<b>PIOPED</b>	Prospective Investigation of Pulmonary Embolism Diagnosis
<b>PMN</b>	Polymorphonuclear
<b>PPV</b>	Positive predictive value
<b>PS</b>	Phosphatidylserine
<b>PSGL-1</b>	P-selectin glycoprotein ligand-1
<b>PT</b>	Prothrombin time
<b>RCT</b>	Randomized clinical trials
<b>rt-P</b>	recombinant tissue plasminogen activator
<b>TCT</b>	thrombin clotting time

<b>Abb.</b>	<b>Full Term</b>
<b>TF</b>	Tissue factor
<b>TFMP</b>	Tissue factor bearing microparticles
<b>TM</b>	Thrombomodulin
<b>TNF-a</b>	Tumor necrosis factor-alpha
<b>tPA</b>	Tissue plasminogen activator
<b>TxA2</b>	Thromboxane a2
<b>UEDVT</b>	Upper extremity deep vein thrombosis
<b>UFH</b>	Unfractionated heparin
<b>uPA</b>	Urokinase-type plasminogen activator
<b>uPAR</b>	Urokinase-type plasminogen activator receptor
<b>VEGF</b>	Vascular endothelial growth factor
<b>VKA</b>	vitamin K antagonist
<b>VTE</b>	Venous thromboembolism
<b>vWF</b>	Von willebrand factor
<b>WBC</b>	White blood count



## ***List of Tables***

<b>Table</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Thrombotic risk factors in cancer patients	26
<b>2</b>	Select biomarkers predictive of cancer-associated thrombosis	33
<b>3</b>	Khorana Predictive Model for Chemotherapy associated VTE	47
<b>4</b>	Well's Score for DVT	60
<b>5</b>	Simplified pulmonary embolism severity index (PESI)	68
<b>6</b>	Characteristic incidence of signs, symptoms and diagnostic indicators in patients with pulmonary embolism in %	71
<b>7</b>	Well's score for pulmonary embolism	72
<b>8</b>	Simplified Well's score for pulmonary embolism	73
<b>9</b>	Revised Geneva for pulmonary embolism and deep vein thrombosis	73
<b>10</b>	Simplified Revised Geneva for pulmonary embolism and deep vein thrombosis	74
<b>11</b>	Charlotte rule for pulmonary embolism and deep vein thrombosis	74

<b>Table</b>	<b>Title</b>	<b>Page</b>
<b>12</b>	Dosing Regimens for Prophylaxis/Treatment of VTE in Patients with Cancer	97
<b>13</b>	Contraindications and Other Considerations to Withhold Therapeutic Anticoagulant Therapy in Patients with Cancer and VTE	99
<b>14</b>	Treatment Guidelines for the Acute Phase of Pulmonary Embolism	100
<b>15</b>	Comparative Properties of Warfarin, Dabigatran, Rivaroxaban, and Apixaban	101
<b>16</b>	Effects of the New Oral Anticoagulants on Routine and Special Coagulation Assays	105
<b>17</b>	Suggested Approaches to Switching to and From the NOAs for Purposes of Therapeutic Anticoagulation	107

## ***List of Figures***

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Potential mechanism of cancer-associated thrombosis.	13
<b>2</b>	Tumor-hemostatic system interactions	14
<b>3</b>	The Coagulation Cascade and Points of Activation by Cancer-Generated Intermediaries	16
<b>4</b>	Microparticle (MP) production and activities in cancer.	17
<b>5</b>	Activated protein C inhibits blood coagulation and enhances endothelial barrier function.	19
<b>6</b>	Principal pathways of tumor cell interaction with the hemostatic system.	21
<b>7</b>	Genetic changes upregulate molecules responsible for neoplastic transformation and tumor procoagulant activity.	24
<b>8</b>	Principal mechanisms of cancer-associate thrombosis. Cancer cells can activate the hemostatic system by different pathways.	25
<b>9</b>	Overview of platelet contribution to tumor metastasis.	33
<b>10</b>	Using Risk Stratification To Improve Risk-Benefit of Outpatient Prophylaxis.	52

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>11</b>	The pathophysiology of right ventricular (RV) dysfunction as a result of acute pulmonary embolism (PE)	56
<b>12</b>	Overall diagnostic algorithm for evaluation of suspected deep vein thrombosis (DVT).	57
<b>13</b>	Ultrasound findings of acute DVT.	62
<b>14</b>	Color Doppler ultrasound image	63
<b>15</b>	The standardized image acquisition technique and computerized image analysis algorithm to calculate thrombus volume using a three-dimensional (3D) duplex ultrasound system.	64
<b>16</b>	The standardized B-mode duplex ultrasound imaging and image processing method to measure thrombus echogenicity.	66
<b>17</b>	An integrated diagnostic algorithm for patients with suspected pulmonary embolism (PE).	67
<b>18</b>	Findings of acute PE on CTPA	76
<b>19</b>	Contrast-enhanced chest computed tomography demonstrating bilateral main pulmonary artery emboli	77
<b>20</b>	Findings of chronic thromboembolic disease on CTPA	78
<b>21</b>	The coagulation cascade and anticoagulants.	89

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>22</b>	Vena cava filters	110
<b>23</b>	CT venogram shows the thrombus lodged in both the inferior vena cava (IVC) and the permanent IVC filter.	112
<b>24</b>	Clinical suspicion (VTE), Upper extremity DVT.	114
<b>25</b>	Clinical suspicion (VTE), Lower extremity DVT.	115
<b>26</b>	Clinical suspicion (VTE), Pulmonary Embolism (PE).	116
<b>27</b>	{BOX A}, Treatment of all VTE.	117
<b>28</b>	(ACCP) American college of chest physicians antithrombotic guidelines, 9 <sup>th</sup> edition Grading system.	118



---

# Introduction

---





---

# Aim of the Study

---

